Minimal residual disease: The role of molecular monitoring in autotransplantation for non-hodgkin’s lymphoma

Bone Marrow Transplantation

Volumn 29, Issue 7, 2002, Pages 581-587

  Galimberti, S ^a   Marasca, R ^b   Caracciolo, F ^a   Fazzi, R ^a   Papineschi, F ^a   Benedetti, E ^a   Guerrini, F ^a   Morabito, F ^c   Oliva, E ^d   Di Renzo, N ^e   Federico, M ^b   Petrini, M ^a   Torelli, G ^b  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c Bone Marrow Transplant Unit   (Italy)

^d Hematology Unit   (Italy)

^e CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

Ex vivo purging; Lymphoma; Minimal residual disease; Molecular detection

Indexed keywords

CELL PROTEIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN HEAVY CHAIN; MELPHALAN; METHOTREXATE; MITOXANTRONE; MOLECULAR MARKER; PREDNISONE; PROTEIN BCL 1; PROTEIN BCL 2; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; ARTICLE; AUTOTRANSPLANTATION; BONE MARROW; BONE MARROW PURGING; CANCER CHEMOTHERAPY; CANCER REGRESSION; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKAPHERESIS; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; NONHODGKIN LYMPHOMA; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTO ONCOGENE; RECURRENCE RISK; RELIABILITY; SAMPLE; SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; BONE MARROW PURGING; COMBINED MODALITY THERAPY; CYCLIN D1; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; GENES, BCL-2; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; LEUKAPHERESIS; LIFE TABLES; LYMPHOMA, HIGH-GRADE; LYMPHOMA, LOW-GRADE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PREDNISONE; PROTO-ONCOGENE PROTEINS C-BCL-2; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VINCRISTINE;

EID: 0036100488     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj/bmt/1703422     Document Type: Article

References (22)

1. Autologous stem cell transplantation in aggressive non-Hodgkin's lymphoma
2. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: Analysis of the PARMA trial
3. Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation
4. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial
5. Detection of minimal residual disease by polymerase chain reaction in B cell malignancies
6. Comparison of different strategies of molecular genetic monitoring following autologous stem cell transplantation in patients with follicular lymphoma
7. High-dose therapy supported with immunomagnetic purged autologous bone marrow in high-grade B cell non-Hodgkin's lymphoma
8. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphomas: Evidence for a role of both chemotherapy and rituximab infusion
9. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease
10. The clinical significance of molecular response in indolent follicular lymphomas
11. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
12. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma
13. Assessment of clonality in cutaneous lymphoid infiltrates by polymerase chain reaction analysis of immunoglobulin heavy chain gene rearrangement
14. Determination of B-cell clonality in paraffin-embedded lymphnodes using the polymerase chain reaction
15. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of BCL2 have residual containing the BCL2 rearrangement at evaluation and after treatment
16. Antigen expression and polymerase chain reaction amplification of mantle cell lymphomas
17. Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high-grade non-Hodgkin's lymphoma
18. Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumour burden: A GOELAMS phase II study
19. Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma: A case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry
20. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma
21. Use of the polymerase chain reaction and direct sequencing analysis to detect cells with the t(14;18) in autologous bone marrow from patients with follicular lymphoma, before and after in vitro treatment
22. Autologous stem cell transplantation (ASCT) with immunologically purged progenitor cells in patients with advanced stage follicular lymphoma after early partial or complete remission: Toxicity, follow up of minimal and survival